Newsfilter article unlocker

We know that one thing on the minds of many hematology oncologists is the continued effort to utilize targeted therapies in AML and many of them have asked us how we see the competitive landscape playing out as we begin to position anamycin for approval. Now our corporate deck really does a good job of walking you through how we see targeted therapies creating an even greater opening for anamycin. The dilemma facing targeted therapies is that they have limited efficacy as monotherapies. So now the focus is on adding them to existing induction therapies like 7 plus 3 or then HMA, and the results are encouraging. But the problem with these new triplet therapies is managing the layered effect of toxicities from three drugs in combination.